Dr Reddy’s Q2 net profit falls 36% to ₹925 crore

SENSEX 73,123.83

 -125.56

NIFTY 22,600.00

 -87.65

CRUDEOIL 9,663.00

+ 179.00

GOLD 142,926.00

 -383.00

SILVER 195,593.00

 -4,006.00

SENSEX 73,123.83

 -125.56

NIFTY 22,600.00

 -87.65

NIFTY 22,600.00

 -87.65

CRUDEOIL 9,663.00

+ 179.00

CRUDEOIL 9,663.00

+ 179.00

GOLD 142,926.00

 -383.00

'; } document.getElementById("lgdv").innerHTML = htmlElements; } function numberformat(i) { return Number(parseFloat(i).toFixed(2)).toLocaleString('en', { minimumFractionDigits: 2 }) } async function gatherResponse(response) { const { headers } = response; const contentType = headers.get('content-type') || ''; if (contentType.includes('application/json')) { return await response.json() } return response.text(); } function getWidth() { if (Math.max(document.body.scrollWidth,document.documentElement.scrollWidth,document.body.offsetWidth,document.documentElement.offsetWidth,document.documentElement.clientWidth) > 991) { document.getElementById("mob").style.display = "none"; document.getElementById("lgdv").style.display = "block"; } else { document.getElementById("mob").style.display = "block"; document.getElementById("lgdv").style.display = "none"; } } getWidth(); THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

Revenue dips 1.5%; results hit by ₹239 crore provision related to Semaglutide API

By BL Hyderabad Bureau

Updated - October 23, 2026 at 06:44 PM. | Hyderabad

Dr Reddy’s Laboratories’ net profit declined 36 per cent to ₹925 crore in the second quarter ended September 2026 on a year-on-year (y-o-y) basis. The total revenue of the Hyderabad-based company declined 1.5 per cent to ₹8,671 crore.

The results were impacted due to ₹239 crore provision towards inventory and associated costs related to Semaglutide API related impact, the company said on Friday.

Published on October 23, 2026

Companies to follow

• Dr Reddys Laboratories Ltd

THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.Sign into Unlock benefits!

• Access 10 free stories per month
• Get notified by email for early preview to new features, discounts & offers